Key points from article :
Apollo Health Ventures and Paul Scherrer Institute (PSI) launched Focal Biosciences to redefine the treatment of age-related diseases.
Cellular reprogramming is a novel approach of resetting damaged or dysfunctional cells to a healthy state, reversing disease mechanisms and stopping detrimental processes to transform the treatment landscape of age-related diseases.
Newly founded entity will initially operate out of the PSI, using its key infrastructure and expertise as part of Apollo's Venture Labs.
“Focal Biosciences is pursuing a unique and innovative approach leveraging an advanced concept of cellular reprogramming, that will enable the development of a novel class of therapies,” said Jan Adams, Venture Partner at Apollo Health Ventures.
“We value Apollo Health Ventures’ and PSI’s commitment to our scientific vision of how to fundamentally change the treatment landscape for a variety of age-related diseases,” said G.V. Shivashankar, Scientific Founder of Focal Biosciences.
Advances in understanding the biology of aging coupled with latest technologies have significantly increased pre-symptomatic detection of age-related damage and dysfunction.
